Treatment of Parkinson's disease should begin with a dopamine agonist

Movement Disorders

Volumn 14, Issue 5, 1999, Pages 725-730

  Montastruc, Jean Louis ^a,b   Rascol, Olivier ^a   Senard, Jean Michel ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Agonists; Bromocriptine; Cabergoline; Dopamine; Early treatment of Parkinson's disease; Lisuride; Parkinson's disease; Pergolide; Pramipexole; Ropinirole

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

DRUG CHOICE; DRUG RECEPTOR BINDING; HUMAN; LONG TERM CARE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

BENZOTHIAZOLES; BROMOCRIPTINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ERGOLINES; HUMANS; INDOLES; LEVODOPA; LISURIDE; PARKINSON DISEASE; PERGOLIDE; RECEPTORS, DOPAMINE D2; THIAZOLES;

EID: 0032737058     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L     Document Type: Review

References (49)

1. Ross EM. Mechanisms of drug action and the relationship between drug concentration and effect. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw Hill, 1996:29-41.
2. Montastruc JL, Rascol O, Senard JM. New directions in the drug treatment of Parkinson's disease. Drugs & Aging 1996;9:169-184.
3. Rascol A, Guiraud B, Montastruc JL, et al. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
4. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
5. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
6. Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998;51(suppl 2):S13-S20.
7. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998;51(suppl 2):S21-S24.
8. Stocchi F. Dopamine agonists in Parkinson's disease. What is their role in early treatment? CNS Drugs 1998;10:159-170.
9. Olanow CW, Jenner P, Brook S. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44: S167-S174.
10. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-863.
11. Montastruc JL, Rascol O, Senard JM. Neuroprotection in Parkinson's disease. Lancet 1996;347:196.
12. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(suppl 1):1-9.
13. Rascol A, Montastruc JL, Guiraud-Chaumeil B, et al. La bromocriptine comme premier traitement de la maladie de Parkinson. Rev Neurol (Paris) 1982;138:401-408.
14. Grimes JD, Delgado MR, Gray P. Low dose bromocriptine in de novo Parkinson's disease: indications, dosage, initial response rate and adverse effects. Neurology 1983;33(suppl):112-118.
15. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow up. Neurology 19887;37:826-828.
16. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3-year follow up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
17. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-339.
18. Rinne UK. Early use of dopamine agonist in the treatment of Parkinson's disease. In: Rinne UK, et al, eds. How to Proceed Today in Treatment, From Basic Research and Early Diagnosis to Long-Term Treatment? International Workshop on Parkinson's Disease. Berlin, 1991:326-336.
19. Hely MA, Morris JGL, Reid WGS, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
20. Bergamasco B, Benna P, Scarzella L. Long-term bromocriptine treatment of de novo patients with Parkinson's disease. Acta Neurol Scand 1990;81:383-387.
21. Nakanishi T, Iwata M, Goto I, et al. Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of Parkinson's disease: final report. Eur Neurol 1992;32(suppl 1):9-22.
22. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13: 234-241.
23. Hubble JP, Joller WC, Certler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18: 338-347.
24. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
25. Kieburts K for the Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 1997;2:125-130.
26. Shannon KM, Bennet JP, Friedmann JM for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
27. Brooks DJ, Abbot RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2-agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998;21: 101-107.
28. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson's disease: a 12-month experience. Ropinirole Study Group. Arch Neurol 1998;55:1211-1216.
29. Bravi D, Lledo A, Rost N, et al. Pergolide monotherapy in early stage Parkinson's disease: a multicentre, international double-blind randomized trial. Mov Disord 1998;13(suppl 2):124.
30. Korczyn AD, Brooks DJ, Brunt ER, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
31. Korczyn AD on behalf of the 053 Study Group. Ropinirole versus bromocriptine in the long-term treatment of early Parkinson's disease. Mov Disord 1998;13(suppl 2):56.
32. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55(suppl 1):23-30.
33. Przuntek H, Welzel D, Blümmer E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992;43:357-363.
34. Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the Prado study. J Neurol Transm 1996;103:699-715.
35. Gimenez-Roldan S, Tolosa E, Bruguera A, et al. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. Clin Neuropharmacol 1997;20:67-76.
36. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8: 257-262.
37. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-27.
38. Montastruc JL, Rascol O, Senard JM, et al. A randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
39. Olanow CW, Hauser RA. The treatment of early Parkinson's disease. In: Marsden CD, Fahn S, eds. The Assessment and Therapy of Parkinsonism, New Trends in Clinical Neurology. Parthenon Publishing, Carnforth, 1990:77-88.
40. Ahbskog JE, Muenter MD, Bayley PA, et al. Dopamine agonist treatment of fluctuating parkinsonism. D2 (controlled release MK-458) versus combined D1 and D2 (pergolide). Arch Neurol 1992; 49:560-568.
41. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998;13:39-45.
42. Montastruc JL, Bagheri H, Lapeyre-Mestre M, et al. Pharmacovigilance and pharmacoepidemiology: principles, definition, methods and current trends in neurology. Rev Neurol (Paris) 1999;155:312-324.
43. Montastruc JL, Montastruc P. Antihypertensive properties of bromocriptine in neurogenic hypertensive dogs. Arch Int Pharmacodyn 1981;252:210-218.
44. Hely MA, Morris JGL, Traficante R, et al. The Sydney Multicentre Study of Parkinson's disease: mortality with low dose bromocriptine or levodopa-carbidopa after 10 years. Mov Disord 1998;13 (suppl 2):185.
45. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998; 51:811-814.
46. Simonetta M, Schmitt L, Montastruc JL, et al. Neuropsychiatric side effects of bromocriptine in Parkinson's disease. Rev Neurol (Paris) 1987;143:608-611.
47. Dodel RC, Eggert KM, Singer MS, et al. Cost of drug treatment in Parkinson's disease. Mov Disord 1998;13:249-254.
48. Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-314.
49. Hoerger TS, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998;14:541-557.